Dexmedetomidine Versus Adenosine: Electrophysiologic Effects and Therapeutic Use for Terminating Supraventricular Tachycardia.

Trial Profile

Dexmedetomidine Versus Adenosine: Electrophysiologic Effects and Therapeutic Use for Terminating Supraventricular Tachycardia.

Completed
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 30 Mar 2017

At a glance

  • Drugs Dexmedetomidine (Primary) ; Adenosine
  • Indications Supraventricular tachycardia
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Feb 2017 Treatment arms has been changed from 2 to 1. Dose of intervention has been changed from 1mcg to 2mcg and principal investigatior also got changed.
    • 07 Feb 2017 Status changed from recruiting to completed.
    • 06 Feb 2012 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top